NEWS & MEDIA

In the News

ivWatch Chief Nursing Officer Talks Product Support in MD+DI
ivWatch’s Susan Brown recently shared insights on device implementation in the Medical Device and Diagnostic Industry (MD+DI) article, “Training the Trainers to Ensure Customer Satisfaction.” In the piece, she taps on her clinical research experience and training program development for ivWatch to inform readers of best practices during the various stages of the device buying cycle. The article highlights device evaluations, training, implementation, and the need for high-quality medical devices to be accompanied by high-touch servicing models to keep customer satisfaction high. MD+DI is a resource for manufacturers of medical devices and in vitro diagnostic products with a mission to help medtech professionals develop, design, and manufacture products that comply with complex and demanding regulations and evolving market requirements.
Read her article here.

ivWatch Intellectual Property Grows with Three International Patents

Latest patent grants cover core product technologies

HAMPTON, VA., February 8, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of peripheral intravenous (PIV) infiltrations and extravasations, recently had three patent applications granted by the Japanese and Australian Patent Offices expanding the company’s intellectual property portfolio.

“Today’s healthcare marketplace is growing increasingly competitive with the introduction of new devices and technologies, so we must continue to build on our successes in this space by protecting our innovations,” said Gary Warren, president and CEO of ivWatch. “Our philosophy regarding intellectual property is to aggressively protect our proprietary technology to expand our product portfolio and develop licensing opportunities with strategic partners.”

Granted Japanese Patent Application No. 2015-553708 is for a core technology regarding the geometry of ivWatch sensor heads – for both the fiber optic and electronic systems – which has secured ivWatch’s position as a first, and only, technology of its kind in the market. Optimal light angles and distances of the various sensor parts allow the technology to detect infiltrations with high sensitivity to aid healthcare providers in an early diagnosis of these most serious events during intravenous (IV) therapy.

Granted Japanese Patent Application No. 2015-510267 is for a second core technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, more commonly known as receptacles, may be independent of the dressings that cover infusion sites during IV therapy or may be integrated with those dressings. The granting of these applications comes just months after ivWatch entered into a licensing and distribution agreement with Terumo Corporation helping to advance patient safety in Japan and on a global scale.

Australian Patent No. 2013316021 is directed to a third core technology for mitigating the effects of tissue blood volume changes. The Australian patent corresponds to U.S. Patent No. 9,326,686, for solving motion issues related to continuous PIV therapy monitoring. The patent is directly related to the ability of the ivWatch Model 400 to reduce the number of “false” notifications helping combat an epidemic of clinicians becoming desensitized to alarms, many of which are false or clinically irrelevant.

These new grants are in addition to the two patents already in ivWatch’s intellectual property portfolio, which also includes numerous utility patent applications. This portfolio gives ivWatch the right to prevent others from making, using or selling our products in the U.S. and major international markets.

There is a rapid demand for breakthrough technology as more healthcare facilities focus on value-based care to lower costs and improve patient safety and satisfaction. IV infiltration and extravasation is a major problem as it can lead to serious medical complications and even amputation. The ivWatch Model 400 continuously monitors a patient’s PIV for evidence of infiltrations and extravasations, which occur when medication or fluid leaks into the surrounding tissue. Early detection of those failures via ivWatch biosensor technology helps to minimize injuries associated with this common complication of IV therapy.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivWatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

Download Center

ivWatch company and product information is available. If you would like more information, please contact us at info@ivwatch.com with your request.

Press kit: Download

The press kit contains ivWatch logos, product images, and executive bios

ivWatch Monitored PIV Infographic: Download

ivWatch Patient Safety Infographic: Download

ivWatch Company Brochure: Download

ivWatch Pediatric Brochure: Download

ivWatch ICU Brochure: Download

ivWatch OR/Anesthesia Brochure: Download

ivWatch Med/Surg Brochure: Download

ivWatch Oncology Brochure: Download

Model 400 Fact Sheet: Download

Model 400 Product Manual: Download

OEM Tech Sheet: Download

For media inquiries, please contact:

Amara Betoney
ivWatch Manager, Public Relations
Direct: 757-224-2606
Office: 855-489-2824 ext. 7007
Mobile:757-660-4949
amara.betoney@ivwatch.com

Pin It on Pinterest